Guava RapidQuant™ Enables Quantification of Secreted IgG Antibodies
Complete the form below to unlock access to ALL audio articles.
Guava Technologies, Inc. has launched a new and enhanced version of its Guava RapidQuant™ IgG Antibody Quantification Assays for mouse and human antibodies. The assays help users select of optimal clones from hybridoma screens.
According to David King, VP R&D and Operations, Guava Technologies, these mix-and-read, bead-based assays were developed with users in mind. "We wanted to give scientists an assay that almost ran itself," said David. "The protocol is basically three simple steps; we eliminated the time-consuming sample preparation and washes common with many ELISAs."
Users are adopting the assays as critical tools for antibody research: "The RapidQuant IgG Assay expands our toolbox for differentiating monoclonal antibody cultures and is an essential tool when sub-cloning to obtain higher antibody secretors," said Dr. John Kenney, President, Antibody Solutions, Mountain View, California, USA.
Results from RapidQuant Assay are read on a plate-based benchtop flow cytometer, such as the Guava EasyCyte™ Plus System, and are equivalent to those obtained with traditional ELISAs.
The assay-specific RapidQuant Software gives users easy and complete data acquisition and analysis capabilities in a single program. It leads users directly to results while also offering customisable options for flexibility. And, assay processes are simplified with easy set-up, straightforward data acquisition, automatic analysis, and extensive data management options, the company says.
The end result is an ideal assay for hybridoma screening that combines the reliability of flow cytometry with the convenience of a microplate-based format.
